BD200 / Biolojic Design - LARVOL DELTA

The multibody drug conjugate (MDC) BD200 mediates anti-tumor activity through a novel dual-targeting mode (AACR 2026) - "The preclinical data suggest that a bivalent MDC addresses the challenge of tumor heterogeneity, while retaining the developability and the functional traits of a natural, simple, symmetrical human IgG. This may allow BD200 to drive deeper responses in more tumor types and more patients than existing ADCs."

Oncology • NECTIN4